United Therapeutics Corporation Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
United Therapeutics Corporation (UTHR) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $5.90 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-27.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2019-02-27
- United Therapeutics Corporation adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2016 was $5.90M, a 84.22% decline from fiscal 2015.
- United Therapeutics Corporation adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2015 was $37.40M, a 21.43% increase from fiscal 2014.
- United Therapeutics Corporation adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2014 was $30.80M, a 231.22% increase from fiscal 2013.
- United Therapeutics Corporation adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2013 was $9.30M, a 204.49% increase from fiscal 2012.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month as first filed |
|---|---|---|
| 2016-12-31 | $5.90M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $37.40M 10-K · filed 2018-02-21 | $37.43M 10-K · filed 2016-02-25 |
| 2014-12-31 | $30.80M 10-K · filed 2017-02-22 | $30.84M 10-K · filed 2015-02-24 |
| 2013-12-31 | $9.30M 10-K · filed 2016-02-25 | |
| 2012-12-31 | $3.05M 10-K · filed 2015-02-24 | |
| 2011-12-31 | $11.35M 10-K · filed 2014-02-25 | |
| 2010-12-31 | $23.83M 10-K · filed 2013-02-26 | |
| 2009-12-31 | $4.41M 10-K · filed 2012-02-28 | |
| 2008-12-31 | $38.36M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |